Citations

Clear

20 citation(s) found for "Thompson, Robert H".

Expert Recommendations for Rapid Response to Positive Newborn Screen for Infantile Krabbe Disease
Thompson-Stone, Robert , White, Amy , Rubin, Jennifer , Rajan, Deepa , Matern, Dietrich , Kurtzberg, Joanne , Orsini, Joseph J. , Shenoy, Shalini , Mallack, Eric J. , Ream, Margie , White, Amy L , Rubin, Jennifer P , Rajan, Deepa Soundara , Ream, Margie A , Kurtzberg, Joanne , Orsini, Joseph J

Mayo Clinic

Neurology Genetics | April 22, 2026 | Volume: 12 | Issue: 3 | Pages: No page available

10.1212/nxg.0000000000200383 | PMID 42040243 Get It

Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study.
Ghoreifi, Alireza, Sobhani, Sina , Lopez, Carlos Rivera, Helstrom, Emma, Deol, Ekamjit S. , KHENE, Zine-Eddine, Gill, Inderbir, Thompson, Robert Houston, Tachibana, Isamu Tachibana, Khanna, Abhinav, Lee, R. Jeffrey, Uzzo, R., Margulis, Vitaly, Singla, Nirmish, Djaladat, Hooman, Ghoreifi, Alireza , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Basin, Michael F. , Lopez, Carlos A. Rivera , Khene, Z. , Gill, Inderbir, Thompson, R. Houston, Tachibana, Isamu , Margulis, Vitaly, Djaladat, Hooman

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 454-454

10.1200/jco.2026.44.7_suppl.454 Get It

454 Background: Immune checkpoint inhibitor (ICI)-based combination therapy has become the standard of care for advanced renal cell carcinoma (RCC). A pathologic complete response (pCR) in the primary tumor may be observed in up to one-third of patients; however, data on the outcomes of these patients remain limited. This study aimed to evaluate the clinical outcomes of patients who achieved a pCR following ICI therapy. Methods: Patients with advanced RCC who underwent nephrectomy following ICI therapy were evaluated across five high-volume U.S. academic centers between 2015 and 2023. Clinical characteristics and outcomes were compared between those with and without a pCR in the primary tumor (ypT0N0/Nx). Multivariable logistic regression models were used to identify factors associated with pCR. Recurrence-free (RFS) and overall survival (OS) rates were estimated using the Kaplan-Meier (KM) method. Results: A total of 182 patients were included (Table 1). Among all patients, downstaging to ≤ypT1N0/Nx was observed in 45 patients (25%), of whom 21 (11%) achieved a pCR. In multivariable analysis, the presence of clinical thrombus was marginally associated with a lower likelihood of achieving pCR (odds ratio [95% CI]: 0.39 [0.15–1.00], p=0.06). During a median follow-up of 25 months, 70 patients (38%) experienced recurrence, including 4 (2%) in the pCR group. Median time to recurrence was 7.5 months. KM analysis demonstrated a higher estimated 5-year RFS in the pCR group compared to those with residual disease; however, the difference was not statistically significant (68% vs. 54%, p=0.2). In addition, OS rates were comparable between the two groups. Conclusions: In our cohort, 11% of patients who underwent nephrectomy following ICI therapy for advanced RCC showed pCR, which correlated with improved oncologic outcomes. Despite the lower recurrence rates observed in the pCR group, sustained long-term surveillance remains necessary due to the continued, albeit reduced, risk of disease recurrence. Clinical characteristics of patients who underwent post-ICI nephrectomy, stratified by their pathologic complete response (pCR). Variable pCR (n=21) No pCR (n=161) p-value Median (IQR) age, year 61 (56 – 70) 64 (56 – 71) 0.46 Gender (male), n (%) 15 (71) 118 (73) 0.8 Tumor advancement, n (%) Locally advanced Metastatic 2 (10)19 (90) 36 (22)125 (78) 0.26 Risk group (for metastatic), n (%) Favorable Intermediate Poor 3 (25)6 (50)3 (25) 38 (34)59 (54)13 (12) 0.42 ICI regimen, n (%) ICI monotherapy ICI+ICI ICI+TKI 4 (19)9 (43)8 (38) 46 (28)64 (40)51 (32) 0.64 Immunotherapy cycles (>4), n (%) 8 (50) 49 (37) 0.42 Median (IQR) clinical tumor size, cm 9.3 (6.7 – 11.9) 8.4 (6.6 – 12) 0.68 Clinical nodal involvement, n (%) 8 (38) 53 (33) 0.63 Clinical thrombus, n (%) 12 (57) 60 (37) 0.1 ICI: immune checkpoint inhibitor; TKI: tyrosine kinase inhibitor.
Low Psychosine in Krabbe Disease with Onset in Late Infancy: A Case Report
Corre, Camille, Matern, Dietrich , Pellegrino, Joan E., Saavedra‐Matiz, Carlos A., Orsini, Joseph J. , Thompson-Stone, Robert

Mayo Clinic

International Journal of Neonatal Screening | May 31, 2021 | Volume: 7 | Issue: 2 | Pages: 28

10.3390/ijns7020028 | PMID 34071213 Get It

Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient’s evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study
Vargas, Carlos , Thorpe, C.S. , Dueck, Amylou C. , Tenner, Kathleen , Davidson, Nancy E. , Martino, Silvana, Pisansky, Thomas M. , Hwang, E. Shelley , Halyard, Michele Y. , Pockaj, Barbara A. , Perez, Edith A. , Hwang, E. Shelley , Thorpe, Cameron S , Tenner, Kathleen S, Dueck, A. C.

Mayo Clinic

Cancer | September 21, 2020 | Volume: 126 | Issue: 24 | Pages: 5239-5246

10.1002/cncr.33154 | PMID 32931029 Get It

BackgroundThe goal of this study was to assess the impact of trastuzumab on locoregional failure.METHODSThe analysis included 2763 patients with HER2‐positive (HER2+) breast cancer who were randomly assigned to adjuvant doxorubicin (A), cyclophosphamide (C), paclitaxel (T) and trastuzumab (H) (arm A, AC→T [n = 922]; arm B, AC→T→H [n = 988]; arm C, AC→T+H→H [n = 853]). Radiotherapy was given after AC→T concurrently with H. Radiotherapy was given after lumpectomy (L) or after mastectomy (M) with ≥4 positive lymph nodes but was optional for 1 to 3 positive lymph nodes. Locoregional failures at 10 years (LFR10) as first events were compared using competing risk analysis.ResultsThe median follow‐up was 13.0 years. The first site of failure was local‐only in 96 cases, locoregional in 16 cases, regional in 32 cases, and not specified in 2 cases; LFR10 was 4.8% (95% CI 4.1%‐5.7%). LFR10 was 5.5% (95% CI 4.3%‐7.2%), 4.9% (95% CI 3.7%‐6.4%), and 2.8% (95% CI 1.9%‐4.1%) in arms A, B, and C (B vs A: hazard ratio [HR] 0.91, P = .62; C vs A: HR 0.72, P = .12). For estrogen receptor–positive patients, LFR10 was 3.7% (95% CI 2.8%‐4.8%) and for estrogen receptor–negative patients, it was 6.1% (95% CI 5.0%‐7.4%; HR 0.61, P = .004). Local treatment included L+RT (n = 1044 [38%]), M+RT (n = 1025 [37%]), and M (n = 694 [25%]). LFR10 was 6.% (95% CI 5.0%‐7.8%), 3.0% (95% CI 2.1%‐4.3%), and 5.5% (95% CI 4.0%‐7.4%) for L+RT, M+RT, and M, respectively (M+RT vs L+RT: HR 0.43, P < .001; M vs L+RT: HR 0.88, P = .57). For 1 to 3 positive lymph nodes, LFR10 was 6.5% (95% CI 4.8%‐8.9%), 4.1% (95% CI 2.4%‐7.0%), and 4.3% (95% CI 2.9%‐6.5%) in L+RT, M+RT, and M, respectively (M vs L+RT: HR 0.68, P = .14; M vs M+RT: HR 1.2, P = .6).ConclusionLow 10‐year LFRs were seen regardless of trastuzumab use. Differences in local therapy in patients with 1 to 3 positive lymph nodes did not appear to improve local control. Local therapy studies for HER2+ and other tumor characteristics are important as the role of local therapies continues to evolve.
Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome
Makhani, Naila , Sıva, Aksel , Narula, Sona , Wassmer, Evangeline , Brassat, David, Brenton, J. Nicholas , Cabre, Philippe, Carra‐Dallière, Clarisse , Dubief, Françoise Durand, Inglese, Matilde , Langille, Megan, Mathey, Guillaume , Pelletier, Jean , Reich, Daniel S. , Rojas, Juan Ignacio , Shabanova, Veronika , Shapiro, Eugene D. , Stone, Robert T, Tenembaum, Sílvia , Tintoré, Mar , Uygunoğlu, Uğur , Vargas, Wendy , Venkateswaren, Sunita, Kantarci, Orhun H. , Pelletier, Daniel , Durand‐Dubief, Françoise , Carra Dallière, Clarisse , Reich, Daniel S , Tintoré, Mar , Brenton, J Nicholas , Siva, Aksel , Lebrun‐Frénay, Christine , Seze, Jerome De , Neuteboom, Rinze Frederik , Pohl, Daniela , Stone, Robert Thompson, Vermersch, Patrick , Okuda, Darin T. , Wassmer, Evangeline , Durand-Dubief, Françoise

Mayo Clinic

Multiple Sclerosis Journal - Experimental, Translational and Clinical | March 21, 2019 | Volume: 5 | Issue: 1 | Pages: No page available

10.1177/2055217319836664 | PMID 30915227 Get It

Background Steps towards the development of diagnostic criteria are needed for children with the radiologically isolated syndrome to identify children at risk of clinical demyelination. Objectives To evaluate the 2005 and 2016 MAGNIMS magnetic resonance imaging criteria for dissemination in space for multiple sclerosis, both alone and with oligoclonal bands in cerebrospinal fluid added, as predictors of a first clinical event consistent with central nervous system demyelination in children with radiologically isolated syndrome. Methods We analysed an international historical cohort of 61 children with radiologically isolated syndrome (≤18 years), defined using the 2010 magnetic resonance imaging dissemination in space criteria (Ped-RIS) who were followed longitudinally (mean 4.2 ± 4.7 years). All index scans also met the 2017 magnetic resonance imaging dissemination in space criteria. Results Diagnostic indices (95% confidence intervals) for the 2005 dissemination in space criteria, with and without oligoclonal bands, were: sensitivity 66.7% (38.4–88.2%) versus 72.7% (49.8–89.3%); specificity 83.3% (58.6–96.4%) versus 53.9% (37.2–69.9%). For the 2016 MAGNIMS dissemination in space criteria diagnostic indices were: sensitivity 76.5% (50.1–93.2%) versus 100% (84.6–100%); specificity 72.7% (49.8–89.3%) versus 25.6% (13.0–42.1%). Conclusions Oligoclonal bands increased the specificity of magnetic resonance imaging criteria in children with Ped-RIS. Clinicians should consider testing cerebrospinal fluid to improve diagnostic certainty. There is rationale to include cerebrospinal fluid analysis for biomarkers including oligoclonal bands in planned prospective studies to develop optimal diagnostic criteria for radiologically isolated syndrome in children.